Imaging pathological tau in atypical parkinsonian disorders

Current Opinion in Neurology

Volumn 28, Issue 4, 2015, Pages 447-452

  Coakeley, Sarah ^a,b,c   Strafella, Antonio P ^a,b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Atypical parkinsonian disorders; Corticobasal degeneration; PET; Progressive supranuclear palsy; Tauopathy

Indexed keywords

ALZHEIMER DISEASE; ATYPICAL PARKINSONISM; CORTICOBASAL DEGENERATION; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL NEUROIMAGING; HUMAN; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; TAUOPATHY; BRAIN; METABOLISM; NEUROIMAGING; PATHOLOGY; PROCEDURES; SCINTISCANNING;

TAU PROTEIN;

BRAIN; HUMANS; NEUROIMAGING; PARKINSONIAN DISORDERS; TAU PROTEINS;

EID: 84941194984     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000210     Document Type: Review

References (39)

1. Stamelou M, Bhatia K.P. Atypical parkinsonism: diagnosis and treatment. Neurol Clin 2015; 33:39-56.
2. Stamelou M, Hoeglinger GU. Atypical parkinsonism: an update. Curr Opin Neurol 2013; 26:401-405.
3. Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P. Developments in tau PET imaging. Can J Neurol Sci 2014; 41:547-553.
4. Villemagne V, Fodero-Tavoletti M, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet 2015; 14:114-124.
5. Noble W, Hanger DP, Miller CCJ, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013; 4:83.
6. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12:609-622.
7. Fodero-Tavoletti M, Furumoto S. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res 2014; 6:1-10.
8. Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med 2014; 55:871-874.
9. Murray M, Kouri N, Lin W. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6:1-13.
10. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neu-roimaging studies. J Alzheimers Dis 2014; 42:421-429.
11. Gerhard A. Imaging of neuroinflammation in parkinsonian syndromes with positron emission tomography. Curr Neurol Neurosci Rep 2013; 13:405.
12. Devous MD, Joshi AD, Navitsky Ma, et al. Test-retest data for the tau PET imaging agent 18F-AV-1451 (previously, 18F-T807). Alzheimer Dement 2014; 10:901.
13. Fawaz M, Brooks A. Affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis. ACS Chem 2014; 5:718-730.
14. Armstrong Ra, Cairns NJ. Spatial patterns of the tau pathology in progressive supranuclear palsy. Neurol Sci 2013; 34:337-344.
15. Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis 2013; 36:145-153.
16. Golbe L. Progressive supranuclear palsy. Semin Neurol 2014; 34:151-159.
17. Liscic RM, Srulijes K, Gröger a, et al. Differentiation of progressive supra-nuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand 2013; 127:362-370.
18. Grijalvo-Perez A, Litvan I. Corticobasal degeneration. Semin Neurol 2014; 34:160-173.
19. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496-503.
20. Wood H. Alzheimer disease: [11C]PBB3-A new PET ligand that identifies tau pathology in the brains of patients with AD. Nat Rev Neurol 2013; 9:599.
21. Mathis CA, Klunk WE. Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture. Neuron 2013; 79:1035-1037.
22. Xia C-F, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimer Dement 2013; 9:666-676.
23. Chien DT, Bahri S, Szardenings a K, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34:457-468.
24. Dickerson B, Domoto-Reilley K, Daisy S, Brickhouse M.Imaging tau pathology in vivo in FTLD: initial experience with [18F] T807 PET. Alzheimer Dement 2014; 10:115.
25. Hashimoto H, Kawamura K, Igarashi N, et al. Radiosynthesis, photoisomeriza-tion, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 2014; 55:1532-1538.
26. Maruyama M, Shimada H, Suhara T, et al. Article imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79:1094-1108.
27. Suhara T, Shimada H. In vivo tau PET imaging using PBB3 in Alzheimer's disease and non-Alzheimer's disease tauopathies. Soc Nucl 2014; 55:11-12.
28. Shinotoh H, Shimada H, Hirano S, et al. Imaging of tau pathology in patients pith non-Alzheimer'S disease tauopathies by [11C]PBB3-PET. Alzheimer Dement 2014; 10:6-7.
29. Harada R, Okamura N, Furumoto S, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur JNucl Med Mol Imaging 2013; 40:125-132.
30. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013; 54:1420-1427.
31. Ishiki A, Furumoto S, Harada R, et al. Accumulation of the novel tau imaging tracer 18F-THK-5117 is associated with brain atrophy in Alzheimer's disease. Alzheimer Dement 2014; 10:131.
32. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Noninvasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137:1762-1771.
33. Okamura N, Furumoto S, Harada R, Furukawa K. In vivo selective imaging of tau pathology in Alzheimer's disease with 18F-THK5117. J Nucl Med 2014; 55:18-19.
34. Chien DT, Szardenings a K, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014; 38:171-184.
35. Pressman PS, Miller BL. Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry 2013; 75:574-581.
36. Kobylecki C, Jones M, Thompson J, Richardson A. Cogntive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotem-poral dementia. J Neurol 2015; 262:916-922.
37. Diehl-Schmid J, Onur O, Kuhn J, et al. Imaging frontotemporal lobar degeneration. Curr Neurol Neurosci Rep 2014; 14:1-11.
38. Ahmed RM, Paterson RW, Warren JD, et al. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry 2014; 85:1426-1434.
39. Holmes HE, Ismail O, Wells J, et al. An imaging strategy to characterise tau pathology in vivo in a model of Alzheimer's disease using multiparametric MRI. Alzheimer Dement 2014; 10:114-115.